“Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver ...

BeiGene has won approval from the US Food and Drug Administration for its PD-1 inhibitor Tevimbra (tislelizumab) in combination with chemotherapy to treat advanced gastric or gastroesophageal ...

Tevimbra plus chemotherapy reduced the risk of death by 20% compared with placebo plus chemotherapy. The Food and Drug Administration (FDA) has approved Tevimbra ® (tislelizumab-jsgr) for use in ...

Tevimbra is under clinical development by BeiGene and currently in Phase I for Urethral Cancer. According to GlobalData, Phase I drugs for Urethral Cancer does not have sufficient historical data to ...

Approval of Tevimbra was supported by the RATIONALE-305 Phase III trial, which demonstrated a significant overall survival benefit in patients with unresectable or metastatic HER2-negative gastric or ...

BeiGene (BGNE), a global oncology company that intends to change its name to BeOne Medicines, announced the U.S. FDA has approved Tevimbra in ...

New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA ...

(RTTNews) - BeiGene (BGNE) announced the FDA has approved TEVIMBRA, in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic ...

SAN MATEO, Calif., December 27, 2024--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd ...

"Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver ...